NCT00102037View on ClinicalTrials.gov

Use of Activated Recombinant FVII in Spinal Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Acquired Bleeding DisorderSpinal Fusion
Interventions
DRUG

eptacog alfa (activated)

Trial Locations (14)

15213

Novo Nordisk Investigational Site, Pittsburgh

19107

Novo Nordisk Investigational Site, Philadelphia

20007

Novo Nordisk Investigational Site, Washington D.C.

22908

Novo Nordisk Investigational Site, Charlottesville

30322

Novo Nordisk Investigational Site, Atlanta

33136

Novo Nordisk Investigational Site, Miami

60612

Novo Nordisk Investigational Site, Chicago

75093

Novo Nordisk Investigational Site, Plano

75246

Novo Nordisk Investigational Site, Dallas

95817

Novo Nordisk Investigational Site, Sacramento

94143-0728

Novo Nordisk Investigational Site, San Francisco

07103

Novo Nordisk Investigational Site, Newark

23298-0541

Novo Nordisk Investigational Site, Richmond

98104-2499

Novo Nordisk Investigational Site, Seattle

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY